NASDAQ:MGTA Magenta Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Magenta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.25 +0.02 (+1.63%) (As of 06/28/2022 11:46 AM ET) Add Compare Share Today's Range$1.25▼$1.2750-Day Range$0.97▼$1.8952-Week Range$0.92▼$10.84Volume130 shsAverage Volume352,114 shsMarket Capitalization$73.50 millionP/E RatioN/ADividend YieldN/APrice Target$8.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGTA Stock Forecast (MarketRank)Overall MarketRank™2.21 out of 5 starsMedical Sector363rd out of 1,436 stocksPharmaceutical Preparations Industry157th out of 687 stocksAnalyst Opinion: 3.4Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingMagenta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.17, Magenta Therapeutics has a forecasted upside of 548.1% from its current price of $1.26.Amount of Analyst CoverageMagenta Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.9 Community Rank Outperform VotesMagenta Therapeutics has received 157 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMagenta Therapeutics has received 111 “underperform” votes. (Add your “underperform” vote.)Community SentimentMagenta Therapeutics has received 58.58% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Magenta Therapeutics and other stocks. Vote “Outperform” if you believe MGTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGTA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMagenta Therapeutics does not currently pay a dividend.Dividend GrowthMagenta Therapeutics does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Magenta Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.18% of the stock of Magenta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.63% of the stock of Magenta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Magenta Therapeutics are expected to grow in the coming year, from ($1.37) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Magenta Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Magenta Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMagenta Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Magenta Therapeutics (NASDAQ:MGTA)Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More MGTA Stock News HeadlinesJune 27, 2022 | americanbankingnews.comMagenta Therapeutics, Inc. (NASDAQ:MGTA) Receives $8.17 Average Target Price from BrokeragesJune 5, 2022 | americanbankingnews.com-$0.33 Earnings Per Share Expected for Magenta Therapeutics, Inc. (NASDAQ:MGTA) This QuarterMay 17, 2022 | seekingalpha.comMagenta Therapeutics GAAP EPS of -$0.39May 16, 2022 | finance.yahoo.comMagenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program HighlightsMay 16, 2022 | finance.yahoo.comAfter Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)May 16, 2022 | finance.yahoo.comMagenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia TrialMay 10, 2022 | finance.yahoo.comHere's Why We're Watching Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn SituationApril 14, 2022 | finance.yahoo.comMagenta Therapeutics Trims R&D, Cuts WorkforceApril 14, 2022 | finance.yahoo.comStem cell startup cuts staff by 14%April 14, 2022 | seekingalpha.comMagenta Therapeutics prioritizes operational spending on MGTA-117 program, cuts workforceApril 14, 2022 | finance.yahoo.comMagenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash RunwayMarch 10, 2022 | markets.businessinsider.comDGAP-News: Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117March 8, 2022 | benzinga.comRecap: Magenta Therapeutics Q4 EarningsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGTA CUSIPN/A CIK1690585 Webwww.magentatx.com Phone(857) 242-0170FaxN/AEmployees75Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today6/28/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$8.17 High Stock Price Forecast$20.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+553.3%Consensus RatingModerate Buy Rating Score (0-4)2.83333333333333 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71.14 million Net MarginsN/A Pretax MarginN/A Return on Equity-42.76% Return on Assets-37.78% Debt Debt-to-Equity RatioN/A Current Ratio11.37 Quick Ratio11.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book0.43Miscellaneous Outstanding Shares58,800,000Free Float49,873,000Market Cap$73.50 million OptionableNot Optionable Beta2.25 Magenta Therapeutics Frequently Asked Questions Should I buy or sell Magenta Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Magenta Therapeutics stock. View analyst ratings for Magenta Therapeutics or view top-rated stocks. What is Magenta Therapeutics' stock price forecast for 2022? 6 Wall Street analysts have issued 1 year target prices for Magenta Therapeutics' shares. Their MGTA stock forecasts range from $2.00 to $20.00. On average, they expect Magenta Therapeutics' stock price to reach $8.17 in the next twelve months. This suggests a possible upside of 553.3% from the stock's current price. View analysts' price targets for Magenta Therapeutics or view top-rated stocks among Wall Street analysts. How has Magenta Therapeutics' stock performed in 2022? Magenta Therapeutics' stock was trading at $4.43 at the beginning of 2022. Since then, MGTA shares have decreased by 71.8% and is now trading at $1.25. View the best growth stocks for 2022 here. When is Magenta Therapeutics' next earnings date? Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Magenta Therapeutics. How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics, Inc. (NASDAQ:MGTA) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.05. View Magenta Therapeutics' earnings history. Who are Magenta Therapeutics' key executives? Magenta Therapeutics' management team includes the following people: Dr. Jason Gardner DPHIL, Ph.D., Co-Founder, CEO, Pres & Director (Age 50, Pay $850.45k)Mr. David Wayne Nichols, Chief Technical Officer (Age 58, Pay $388.92k)Mr. Thomas W. Beetham J.D., MBA, Chief Legal Officer & Sec. (Age 52, Pay $517.61k)Mr. Stephen F. Mahoney J.D., MBA, Chief Financial & Operating Officer and Treasurer (Age 51)Dr. Lisa M. Olson Ph.D., Head of Research & Chief Scientific Officer (Age 62)Mr. Jim Haney, Sr. Director of Investor RelationsLyndsey Scull, Director of Corp. CommunicationsMs. Kristen Stants, Chief People Officer (Age 49) (LinkedIn Profile)Ms. Catherine Monaghan, Head of Clinical Devel. OperationsMs. Caren Deardorf, Chief Commercial Officer (Age 57) What is Jason Gardner's approval rating as Magenta Therapeutics' CEO? 3 employees have rated Magenta Therapeutics CEO Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among Magenta Therapeutics' employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Magenta Therapeutics' key competitors? Some companies that are related to Magenta Therapeutics include Precigen (PGEN), AC Immune (ACIU), Seres Therapeutics (MCRB), OptiNose (OPTN), Biotech Acquisition (BIOT), PepGen (PEPG), Verona Pharma (VRNA), Thorne HealthTech (THRN), Inventiva (IVA), Provention Bio (PRVB), InterCure (INCR), Zomedica (ZOM), Alpine Immune Sciences (ALPN), Sernova (SEOVF) and Aadi Bioscience (AADI). View all of MGTA's competitors. What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP). When did Magenta Therapeutics IPO? (MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Magenta Therapeutics' stock symbol? Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA." Who are Magenta Therapeutics' major shareholders? Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Deep Track Capital LP (9.11%), Gilder Gagnon Howe & Co. LLC (5.75%), BlackRock Inc. (3.63%), Vanguard Group Inc. (3.16%), Wellington Management Group LLP (2.22%) and Woodline Partners LP (1.35%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, Jason Gardner, John C Davis Jr, Kristen Stants and Michael P Cooke. View institutional ownership trends for Magenta Therapeutics. Which major investors are selling Magenta Therapeutics stock? MGTA stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Vanguard Group Inc., BlackRock Inc., Harbor Capital Advisors Inc., State Street Corp, Goldman Sachs Group Inc., and Northern Trust Corp. View insider buying and selling activity for Magenta Therapeutics or view top insider-selling stocks. Which major investors are buying Magenta Therapeutics stock? MGTA stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Woodline Partners LP, Deep Track Capital LP, Renaissance Technologies LLC, Federated Hermes Inc., Integral Health Asset Management LLC, JPMorgan Chase & Co., and Cheyne Capital Management UK LLP. View insider buying and selling activity for Magenta Therapeutics or or view top insider-buying stocks. How do I buy shares of Magenta Therapeutics? Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Magenta Therapeutics' stock price today? One share of MGTA stock can currently be purchased for approximately $1.25. How much money does Magenta Therapeutics make? Magenta Therapeutics (NASDAQ:MGTA) has a market capitalization of $73.50 million. The company earns $-71.14 million in net income (profit) each year or ($1.34) on an earnings per share basis. How many employees does Magenta Therapeutics have? Magenta Therapeutics employs 75 workers across the globe. How can I contact Magenta Therapeutics? Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for Magenta Therapeutics is www.magentatx.com. The company can be reached via phone at (857) 242-0170 or via email at [email protected]. This page (NASDAQ:MGTA) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
